A5037122053- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cytomegalovirus and herpesvirus research
- Renal Transplantation Outcomes and Treatments
- Immune Cell Function and Interaction
- Transplantation: Methods and Outcomes
- Acute Lymphoblastic Leukemia research
- Mesenchymal stem cell research
- Hematological disorders and diagnostics
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Platelet Disorders and Treatments
- Lymphoma Diagnosis and Treatment
- Blood disorders and treatments
- Multiple Myeloma Research and Treatments
- Chemotherapy-induced cardiotoxicity and mitigation
- Medical Imaging Techniques and Applications
- Immune cells in cancer
- Mast cells and histamine
- Neutropenia and Cancer Infections
- Eosinophilic Esophagitis
- Histone Deacetylase Inhibitors Research
- Otitis Media and Relapsing Polychondritis
- Parvovirus B19 Infection Studies
National Heart Lung and Blood Institute
2022-2025
National Institutes of Health
2022-2025
Austin Health
2025
Monash Health
2025
The University of Melbourne
2020-2024
Peter MacCallum Cancer Centre
2019-2024
The Royal Melbourne Hospital
2015-2024
Australian Cancer Research Foundation
2020-2023
Austin Hospital
2023
Victorian Comprehensive Cancer Centre
2018
Not available.
Megakaryocytes (MKs) serve diverse roles beyond platelet production, including hematopoietic stem cell maintenance and immune response modulation. In our mouse model of bone marrow failure (BMF), we observed the unexpected persistence MKs despite thrombocytopenia. These exhibited heightened expression activation markers, such as IA-IE CD53, compared to from healthy controls. Single-cell RNA sequencing analysis (scRNA-seq) revealed upregulation pathways downregulation related function...
Summary Uncertainty remains regarding the safety and tolerability of immunosuppressive therapy (IST) with anti‐thymocyte globulin (ATG) cyclosporine (CSA) in older patients. We retrospectively analysed two prospective clinical trials IST treatment‐naïve severe aplastic anaemia (SAA) to assess compared younger Patients ≥18 years age who had received ATG CSA +/− eltrombopag (EPAG) were included. Pre‐treatment baseline characteristics co‐morbidities assessed as predictors therapy‐related...
Poor Graft Function (PGF) is defined by multi-lineage cytopenias with complete donor chimerism post allogeneic transplantation, Risk factors for and subsequent mortality from PGF were assessed in our transplant cohort. Non-sibling [OR 1.97; 95% CI 1.02–3.70], ICU admission 5.28; 2.29–11.88] or blood culture positivity within the first 30 days 1.67; 1.07–2.62], grade III–IV acute graft vs host disease (GVHD) 4.082; 2.31–7.16] CMV viremia 2.43; 1.53–3.88] significantly associated development...
Abstract Objectives Core‐binding factor acute myeloid leukaemia ( CBF AML ) defined by t (8;21)(q22;q22) or inv(16)(p13q22)/ (16;16)(p13;q22) has a favourable prognosis; however, 30%‐40% of patients still relapse after chemotherapy. We sought to evaluate the risk factors for in de novo cohort. Patients/Materials/Methods A retrospective review from four Australian tertiary centres 2001 2012, comprising 40 (8;21) and 30 inv(16) s. Results Multivariate analysis identified age P = .032) white...
Hairy cell leukaemia (HCL) is a rare CD20+ B malignancy characterised by "hairy" cells and extensive bone marrow (BM) infiltration. Frontline treatment with the purine analogue cladribine (CDA) results in highly variable response duration. We hypothesised that analysis of BM tumour microenvironment would identify prognostic biomarkers to CDA. HCL immunology pre post CDA healthy controls were analysed using Digital Spatial Profiling assess expression 57 proteins an panel. A bioinformatics...
Allogeneic stem cell transplantation (alloSCT) is utilised to cure haematological malignancies through a combination of conditioning regimen intensity and immunological disease control via the graft versus tumour (GVT) effect. Currently, conventional myeloablative chemotherapeutic or chemoradiation regimens are associated with significant side effects including host (GVHD), infection, organ toxicity. Conversely, more tolerable reduced (RIC) unacceptably higher rates relapse, partly an excess...
Cytomegalovirus (CMV) infection increases mortality and morbidity following allogeneic hematopoietic stem-cell transplantation (alloHSCT). Universal antiviral prophylaxis with letermovir is effective but unsubsidized in Australia. Valaciclovir demonstrates anti-CMV activity high doses, few current real-world studies explore its use as primary high-risk patients post-alloHSCT.We performed a retrospective analysis of alloHSCT recipients at risk clinically significant CMV (cs-CMVi), defined...
Poor graft function (PGF), manifested by multilineage cytopenias and complete donor chimerism post-allogeneic stem cell transplantation (alloSCT), acquired aplastic anaemia (AA) are immune-mediated bone marrow (BM) failure syndromes with a similar clinical presentation. In this study, we used spatial proteomics to compare the immunobiology of BM microenvironment identify common mechanisms immune dysregulation under these conditions. Archival trephines from patients exhibited downregulation...
Background: Immunosuppressive therapy (IST) with anti-thymocyte globulin (ATG), cyclosporin (CSA) +/- eltrombopag (EPAG) is the now established 1st line non transplant for severe aplastic anemia (SAA), but there are concerns regarding its safety in older patients. We evaluated toxicity of horse or rabbit ATG/CSA EPAG and long-term outcomes our SAA cohort. Aims: 1.Compare type frequency post IST toxicities an (≥60 years) versus younger (<60 years age) cohort patients 2.Evaluate clinical...
Safe outpatient management of acute leukaemia consolidation cycles may enable substantial savings in admission costs. Safety involves the prompt administration antibiotics patients with neutropenic fever. Our unit a metropolitan tertiary referral hospital analysed cohort spanning 10-year period, two key observations: (i) high proportion living distance from and (ii) incidence generally onset fever after severe neutropenia, suggesting this broad applicability approach is unfeasible without...
Abstract Hairy Cell Leukemia (HCL) is a rare CD20+ B cell malignancy characterized by circulating “hairy” cells, extensive bone marrow (BM) infiltration, splenomegaly and pancytopenia. Standard frontline treatment the purine analogue Cladrabine (CDA) for which duration of response highly variable 50% patients relapse within 10 years. We hypothesized that analysis BM tumor microenvironment would identify prognostic biomarkers to CDA. To date HCL immunology has been complicated rarity patient...